Sign in

CIK 0001880438

  • Non-accelerated filer
  • Smaller reporting company
  • Emerging growth company

AN2 Therapeutics, Inc.

Sign in to watch
Ticker
ANTX
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
FY end
Dec 31
Incorporated
DE
Entity type
Operating
EIN
820606654
Phone
+1 650-331-9090
Business address
1300 EL CAMINO REAL, SUITE 100, MENLO PARK, CA, 94025
Open-market buys, last 90 days
$11,602
in 1 filing
Open-market sales, last 90 days
$117,428
in 4 filings, $104K under 10b5-1 plans

Net −$105,826. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.

Date Insider Transaction Shares Price Value Owned after
2024-01-16 Aziz Kabeer Director Sale −15,907 $19.65 $313K 377,542
2024-01-16 Adjuvant Global Health Technology Fund, L.P. 10% owner Sale −84,093 $19.65 $1.7M 1,995,958
2024-01-16 Adjuvant Global Health Technology Fund, L.P. 10% owner Sale −15,907 $19.65 $313K 377,542
2024-01-12 Readnour Robin Shane Director Sale 10b5-1 −706 $21.92 $15K 414,788
2024-01-12 Readnour Robin Shane Director Sale 10b5-1 −719 $21.91 $16K 485,073
2024-01-10 Readnour Robin Shane Director Sale 10b5-1 −1,869 $21.93 $41K 415,494
2024-01-10 Readnour Robin Shane Director Sale 10b5-1 −1,800 $21.92 $39K 485,792
2024-01-09 Krause Kevin Michael Chief Strategy Officer Exercise or conversion 10b5-1 +2,417 $0.42 $1K 4,331
2024-01-09 Krause Kevin Michael Chief Strategy Officer Exercise or conversion 10b5-1 +5,000 $6.60 $33K 9,331
2024-01-09 Krause Kevin Michael Chief Strategy Officer Sale 10b5-1 −7,417 $20.14 $149K 1,914
2024-01-09 Krause Kevin Michael Chief Strategy Officer Exercise or conversion · Stock Option (right to buy) 10b5-1 −2,417 49,868
2024-01-09 Krause Kevin Michael Chief Strategy Officer Exercise or conversion · Stock Option (right to buy) 10b5-1 −5,000 26,832
2024-01-02 Krause Kevin Michael Chief Strategy Officer Exercise or conversion 10b5-1 +2,583 $0.42 $1K 4,497
2024-01-02 Krause Kevin Michael Chief Strategy Officer Sale 10b5-1 −2,583 $20.12 $52K 1,914
2024-01-02 Krause Kevin Michael Chief Strategy Officer Exercise or conversion · Stock Option (right to buy) 10b5-1 −2,583 52,285
2024-01-02 Easom Eric Chief Executive Officer Sale 10b5-1 −2,777 $20.09 $56K 2,130
2023-11-14 Adjuvant Global Health Technology Fund, L.P. 10% owner Sale 10b5-1 −1,522 $16.15 $25K 2,080,051
2023-11-14 Adjuvant Global Health Technology Fund, L.P. 10% owner Sale 10b5-1 −288 $16.15 $5K 393,449
2023-11-14 Aziz Kabeer Director Sale 10b5-1 −1,522 $16.15 $25K 2,080,051
2023-11-14 Aziz Kabeer Director Sale 10b5-1 −288 $16.15 $5K 393,449

Page 12 of 20 · 385 trades